NCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- State
- Under way
- Phase
- Phase 3
- People
- 174 taking part
- Started
- 25 Aug 2020
- Primary completion
- 12 Nov 2024
- Arms
- Ropeginterferon alfa-2b (P1101)
- Results
- None posted
- 26 Feb 2020: Trial registered
- 25 Aug 2020: Trial started